Intestinal Microbiota and Vitamin K Levels in PXE Patients (IMPROVE Study)

Last updated: January 31, 2019
Sponsor: University Hospital, Angers
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT03813550
2018/79
  • Ages > 18
  • All Genders

Study Summary

This study aims to demonstrate a potential association between gut microbiota composition, plasma levels of various forms of vitamin K, and severity of clinical manifestations of Pseudoxanthoma Elasticum (PXE).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with phenotypically and genetically (ABCC6) proven PXE

  • Aged over 18 years

  • Written consent obtained for Angers University Hospital (France) PXE bio-collection

Exclusion

Exclusion Criteria:

  • Patients under the age of 18

  • Patients unwilling to participate in the study, or unable to sign the bio-collectionconsent form

Study Design

Total Participants: 20
Study Start date:
January 21, 2019
Estimated Completion Date:
January 30, 2020

Study Description

Vitamin K deficiency contributes to pathological calcification which underlies the clinical picture of pseudoxanthoma elasticum (PXE), an inherited autosomal recessive disease. A substantial proportion of vitamin K, namely the K2 form (menaquinones), is produced by gut microbiota. In healthy volunteers fecal levels of the major menaquinone producers, Escherichia coli and Bacteroides species, are approximately 5 and 9 log10 CFU/g dry weight respectively. There is however a lack of data on gut microbiota in PXE patients. The objective of our project is to demonstrate a potential association between gut microbiota composition, plasma levels of various forms of vitamin K and severity of clinical manifestations in PXE patients.

This study will be performed as Research surrounding bio collection "Clinical and biological exploration of PXE patients" kept at the Center of Biological Resources of Angers University Hospital (bio collection n° DC 20116-14-67, authorization to transfer n° 2016-27-99). Fecal samples, plasma samples and clinical data will be collected from patients diagnosed with PXE who will be monitored at the Angers University Hospital Referral Center (France) in 2019-2020. Clinical severity of PXE will be assessed using modified Phenodex score. Gut microbiota will be analyzed using metagenomic sequencing. Plasma Vitamin K species and fecal excretion of menaquinones will be assessed using HPLC. Plasma dp-ucMGP (circulating biomarker of vitamin K status) and serum PIVKA-II (protein induced by vitamin K absence-II) will be assessed using immunoassay. Results will be compared to healthy age- and gender-matched controls from the pre-existing Biofortis database.

Connect with a study center

  • Biofortis Mérieux NutriSciences

    Saint-Herblain, Pays De La Loire 44800
    France

    Site Not Available

  • Department of Dermatology, University Hospital of Angers

    Angers, Pays De Loire 49933
    France

    Active - Recruiting

  • Department of Biochemistry, University Maastricht

    Maastricht, 6229
    Netherlands

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.